Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour modelCarole Fournier, Patrice N. Marche|EBioMedicine|2025Cited by 16